New pharma tariffs are pushing biotech firms to consider voluntary pricing deals with the Trump administration for exemptions, Axios reports

The report on new pharma tariffs indicates a significant trade development that could lead to voluntary pricing agreements between biotech firms and the Trump administration.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Novo's (NOVOB DC) Ozempic for Australians is expected to fall from about AUD 300 a month for private patients to a small fraction after Australian patents expire in late 2029 and 2031, according to WA Today

Amazon (AMZN) has quietly expanded its car sales business over the past year and a half, WSJ reports

New pharma tariffs are pushing biotech firms to consider voluntary pricing deals with the Trump administration for exemptions, Axios reports

German 6-Month Bubill Auction 2.310%

An Israeli military official said full operational control of the southern Lebanese town of Bint Jbeil will be achieved within days and that only a small number of “terrorists” remains in the area

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Smaller and midsize companies say they lack the scale and financial flexibility of larger drugmakers to cut prices or reshore production, while carveouts for orphan drugs and cell and gene therapies may soften the impact for some.
Context

This situation is particularly pressing for smaller and midsize companies, as they may struggle with the financial impact compared to larger players. Investors should monitor how these negotiations could influence biotech stock valuations and broader market sentiment in the healthcare sector.

Related headlines

The whole workspace, free to try.

Try it free